Incretins
- Name
- Incretins
- Accession Number
- DBCAT001316
- Description
Peptides which stimulate INSULIN release from the PANCREATIC BETA CELLS following oral nutrient ingestion, or postprandially.
- Drugs
Drug Drug Description Sitagliptin An oral dipeptidyl peptidase-4 (DPP-4) inhibitor used for the management of type 2 diabetes mellitus. Exenatide A GLP-1 agonist used in the management of type 2 diabetes mellitus. Alogliptin A dipeptidyl peptidase-4 (DPP-4) inhibitor used to treat hyperglycemia in patients with type 2 diabetes mellitus. Saxagliptin An DPP-4 inhibitor used for the management of type 2 diabetes mellitus. Liraglutide A GLP-1 analog used in the management of type 2 diabetes mellitus and prevention of cardiovascular complications associated with diabetes. Linagliptin A dipeptidyl peptidase-4 (DPP-4) inhibitor used to manage hyperglycemia in patients with type 2 diabetes mellitus. Albiglutide A GLP-1 agonist used to manage type 2 diabetes mellitus. Gastric inhibitory polypeptide Gastric inhibitory polypeptide is under investigation in clinical trial NCT03081676 (The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without Sulphonylurea). Tirzepatide A dual GIP and GLP-1 receptor agonist used for the treatment of type II diabetes in adults as an adjunct to diet and exercise. - Drugs & Drug Targets